TWI784662B - 苯甲酸鈉之同素異形體形式及其用途 - Google Patents

苯甲酸鈉之同素異形體形式及其用途 Download PDF

Info

Publication number
TWI784662B
TWI784662B TW110129733A TW110129733A TWI784662B TW I784662 B TWI784662 B TW I784662B TW 110129733 A TW110129733 A TW 110129733A TW 110129733 A TW110129733 A TW 110129733A TW I784662 B TWI784662 B TW I784662B
Authority
TW
Taiwan
Prior art keywords
sodium benzoate
disease
disorder
allotropic
sodium
Prior art date
Application number
TW110129733A
Other languages
English (en)
Chinese (zh)
Other versions
TW202144316A (zh
Inventor
蔡果荃
王景正
謝天嵐
Original Assignee
心悅生醫股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 心悅生醫股份有限公司 filed Critical 心悅生醫股份有限公司
Publication of TW202144316A publication Critical patent/TW202144316A/zh
Application granted granted Critical
Publication of TWI784662B publication Critical patent/TWI784662B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TW110129733A 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途 TWI784662B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662412160P 2016-10-24 2016-10-24
US62412160 2016-10-24
US15452137 2017-03-07
US15/452,137 US10336679B2 (en) 2016-10-24 2017-03-07 Polymorphic forms of sodium benzoate and uses thereof

Publications (2)

Publication Number Publication Date
TW202144316A TW202144316A (zh) 2021-12-01
TWI784662B true TWI784662B (zh) 2022-11-21

Family

ID=61970963

Family Applications (5)

Application Number Title Priority Date Filing Date
TW110129733A TWI784662B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途
TW110129735A TWI781723B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途
TW110129734A TWI784663B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途
TW106136543A TWI739938B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途
TW110129732A TWI803935B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
TW110129735A TWI781723B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途
TW110129734A TWI784663B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途
TW106136543A TWI739938B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途
TW110129732A TWI803935B (zh) 2016-10-24 2017-10-24 苯甲酸鈉之同素異形體形式及其用途

Country Status (10)

Country Link
US (1) US10336679B2 (cg-RX-API-DMAC7.html)
EP (1) EP3529229B1 (cg-RX-API-DMAC7.html)
JP (1) JP7141124B2 (cg-RX-API-DMAC7.html)
KR (1) KR102511444B1 (cg-RX-API-DMAC7.html)
CN (1) CN110167909B (cg-RX-API-DMAC7.html)
CA (1) CA3041389A1 (cg-RX-API-DMAC7.html)
IL (2) IL266210B (cg-RX-API-DMAC7.html)
MX (1) MX2019004734A (cg-RX-API-DMAC7.html)
TW (5) TWI784662B (cg-RX-API-DMAC7.html)
WO (1) WO2018077157A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
AU2018371628B2 (en) 2017-11-22 2021-08-12 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
US20210186937A1 (en) * 2018-05-22 2021-06-24 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US20220304962A1 (en) * 2019-04-24 2022-09-29 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
US20260041657A1 (en) * 2024-08-09 2026-02-12 Hsien-Yuan Lane Benzoate for use in preventing or treating cognitive dysfunction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085452A1 (en) * 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5198217A (en) * 1991-09-24 1993-03-30 Choice Pharmaceuticals Topical demulcent for viral and inflammatory diseases of the skin
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6255089B1 (en) * 1997-02-27 2001-07-03 Albany Medical College Constitutively activated serotonin receptors
IN191496B (cg-RX-API-DMAC7.html) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
US6362226B2 (en) * 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
CA2433866A1 (en) 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
JP2006526635A (ja) 2003-06-02 2006-11-24 サマリタン,ファーマスーティカルス,インク. 血清中コルチゾール量を調節する方法および組成物
ZA200605384B (en) 2003-12-29 2007-10-31 Sepracor Inc Benzo[D]isoxazol-3-OL DAAO inhibitors
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
BRPI0509592A (pt) 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
US8263652B2 (en) 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
DE212014000063U1 (de) * 2014-03-24 2015-10-12 China Medical University Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10098861B1 (en) * 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085452A1 (en) * 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 K. Hashimoto et al. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets. 18(9) 2014 Sep p.1049-63. *

Also Published As

Publication number Publication date
CA3041389A1 (en) 2018-05-03
MX2019004734A (es) 2019-09-26
TWI803935B (zh) 2023-06-01
KR20190077003A (ko) 2019-07-02
JP2019532968A (ja) 2019-11-14
KR102511444B1 (ko) 2023-03-16
CN110167909B (zh) 2023-09-19
RU2019113765A3 (cg-RX-API-DMAC7.html) 2021-06-25
RU2019113765A (ru) 2020-11-24
JP7141124B2 (ja) 2022-09-22
TW202144317A (zh) 2021-12-01
TW202144316A (zh) 2021-12-01
TW202146369A (zh) 2021-12-16
TWI781723B (zh) 2022-10-21
TW201829365A (zh) 2018-08-16
EP3529229A1 (en) 2019-08-28
TWI739938B (zh) 2021-09-21
IL266210A (en) 2019-06-30
TWI784663B (zh) 2022-11-21
EP3529229B1 (en) 2024-04-17
WO2018077157A1 (en) 2018-05-03
TW202144315A (zh) 2021-12-01
IL292244A (en) 2022-06-01
US20180346400A9 (en) 2018-12-06
US10336679B2 (en) 2019-07-02
CN110167909A (zh) 2019-08-23
IL266210B (en) 2022-06-01
US20180111891A1 (en) 2018-04-26
EP3529229A4 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
TWI784663B (zh) 苯甲酸鈉之同素異形體形式及其用途
KR102727062B1 (ko) 중수소화 카페인 및 그의 용도
US11369579B2 (en) Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
US20210378266A9 (en) Deuterated caffeine and uses thereof
EP2909203A1 (en) Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e
WO2022056190A2 (en) Deuterated paraxanthine and uses thereof
US20220304962A1 (en) Polymorphic forms of sodium benzoate and uses thereof
RU2782627C2 (ru) Полиморфные формы бензоата натрия и их применения
US20230218623A1 (en) Salts of neuroceuticals and uses thereof
CN119836428A (zh) 新型苯磷硫胺胆碱盐
JP2013193997A (ja) アンジオテンシンii1型受容体拮抗剤及び血圧降下剤
KR20230027210A (ko) 수용성 3-O-아세틸-11-케토-β-보스웰산 및 금속 이온 조성물, 이의 제조방법 및 용도
KR20180054955A (ko) 흡습성이 개선된 글리세릴 포스포릴 콜린을 포함하는 고형 제제, 이의 용도 또는 제조방법